Cambridge Trust Co. Purchases 62 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Cambridge Trust Co. boosted its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 15.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 455 shares of the medical instruments supplier’s stock after buying an additional 62 shares during the quarter. Cambridge Trust Co.’s holdings in West Pharmaceutical Services were worth $180,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $27,000. Quarry LP increased its position in shares of West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services in the 1st quarter worth about $40,000. Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services in the 1st quarter worth about $40,000. Finally, ORG Partners LLC boosted its stake in West Pharmaceutical Services by 820.0% in the 1st quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 123 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

NYSE WST traded down $2.03 during trading hours on Friday, hitting $300.28. The company had a trading volume of 457,026 shares, compared to its average volume of 811,373. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $415.73. The firm has a 50 day simple moving average of $320.53 and a 200 day simple moving average of $354.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The firm has a market capitalization of $21.78 billion, a price-to-earnings ratio of 39.61, a PEG ratio of 10.69 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same quarter in the prior year, the business earned $2.11 EPS. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. Equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current year.

Insider Activity

In other news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.